Coeliac disease

Olympus Announces FDA Clearance of New Endoscopy System and Compatible Endoscopes

Retrieved on: 
Tuesday, May 2, 2023
Xenon, Gastrointestinal disease, ASGE, Histology, TXI, Vein, Brightness, Duodenum, Coeliac disease, American Society for Gastrointestinal Endoscopy, Esophagus, Stomach, Colon, Capillary, BAI, DDW, Crohn's disease, RDI, Gastrointestinal tract, Rectum, Patient, Physician, Colorectal cancer, NBI, Colonoscopy, Observation, Texture, Diagnosis, Ulcer, FDA, GI, Maintenance, Society, Polyp, Medical imaging

CENTER VALLEY, Pa., May 2, 2023 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today the FDA clearance of the new EVIS X1 endoscopy system, along with two compatible gastrointestinal endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract including the esophagus, stomach, and duodenum; and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract including the anus, rectum, sigmoid colon, colon, and ileocecal valve.i

Key Points: 
  • The EVIS X1 endoscopy system features three new enhancements designed to assist physicians in visualizing GI bleeds and anatomical structures.
  • The proven optical-digital technology NBI™ (Narrow Band Imaging™) technology continues to be featured in this next-generation endoscopy system.
  • The EVIS X1 Endoscopy System will be on display and demonstrated in Olympus Booth #3820 at the DDW (Digestive Diseases Week) meeting in Chicago, May 7-9.
  • Information about the EVIS X1 Endoscopy System will be available here: info.olympusamericamarketing.com/X1 .

EQS-News: Immunic to Participate in Investor and Scientific Conferences in May

Retrieved on: 
Wednesday, April 26, 2023
Inflammation, IST, Disease, Biotechnology, COVID-19, DHODH, Virology, Congress, Assistant professor, European, Psychiatry, Human, Poster, Therapy, Coeliac disease, Conference, Safety, Pharmaceutical industry, Neurology, Short course immune induction therapy

NEW YORK, April 26, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:

Key Points: 
  • NEW YORK, April 26, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in May:
    May 2-4: Aegis Virtual Conference.
  • A webcast of the presentation will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .
  • An archived replay will be available on the company’s website for a period of 90 days after the conference.
  • Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present preclinical data on the antiviral properties of dihydroorotate dehydrogenase (DHODH) inhibitors in an oral presentation at this conference in Seattle, WA.

Celiac Disease Foundation, Takeda Announce Early Career Research Award in Celiac Disease

Retrieved on: 
Tuesday, April 25, 2023
Health, Other Science, General Health, Research, Science, Pharmaceutical, Biotechnology, Partnership, Coeliac disease, Multimedia, CDF, Dentistry, Takeda

The Celiac Disease Foundation (CDF), a world leader in patient advocacy, and Takeda Development Center Americas (Takeda), a global biopharmaceutical leader, today are proud to announce the Celiac Disease Foundation–Takeda Early Career Research Award ; an award designed to attract promising researchers to the study of celiac disease.

Key Points: 
  • The Celiac Disease Foundation (CDF), a world leader in patient advocacy, and Takeda Development Center Americas (Takeda), a global biopharmaceutical leader, today are proud to announce the Celiac Disease Foundation–Takeda Early Career Research Award ; an award designed to attract promising researchers to the study of celiac disease.
  • View the full release here: https://www.businesswire.com/news/home/20230425005454/en/
    Through this unrestricted early-career research grant award, CDF and Takeda seek to encourage the development of individuals with research potential to help them prepare for a career of independent or clinical investigation in celiac disease.
  • Stimulating and encouraging innovative research in the basic biomedical and clinical sciences will further understanding of the etiology, pathogenesis, therapy, and prevention of celiac disease.
  • “We greatly appreciate this partnership with Takeda to offer a new grant award that will not only advance our understanding of celiac disease and improve patients’ quality of life, but will also encourage continued progress and collaboration in the field of celiac disease research.”
    “As a research-driven organization, Takeda is committed to celiac disease and supporting both new research and the development of scientific leaders who may advance our understanding of the condition,” said Nelson Cheinquer, Global Medical Affairs lead for Celiac Disease at Takeda.

Celiac Disease Foundation Announces 2023 Global Celiac Disease Research Prize Laureates

Retrieved on: 
Monday, April 17, 2023
Health, Genetics, Other Science, General Health, Research, Science, Prevalence, DRS, Doctor of Philosophy, Intestinal villus, Patient, Risk, MMSc, University of Oxford, Gastrointestinal disease, University, MB, Pediatrics, The Writing on the Wall, Mass, Map, Biomarker, Immunotherapy, Vitamin A, Mackay Base Hospital, Autoimmune disease, Cancer, Partnership, Drug development, Malnutrition, Coeliac disease, Quality of life, Inflammation, Harvard Medical School, Vaccine, Walter, Treatment, International Society, Dentistry, Gastroenterology

The Celiac Disease Foundation is proud to announce the recipients of the 2023 Global Celiac Disease Research Prizes , recognizing outstanding achievements in advancing research and treatment for celiac disease on a global scale.

Key Points: 
  • The Celiac Disease Foundation is proud to announce the recipients of the 2023 Global Celiac Disease Research Prizes , recognizing outstanding achievements in advancing research and treatment for celiac disease on a global scale.
  • The $25,000 Prize for Excellence in Celiac Disease Research, this year awarded to Dr. Robert Anderson, recognizes an investigator whose research has made a significant impact on clinical, translational, or transformative research in celiac disease.
  • “We hope that these prizes will not only recognize their achievements but also encourage continued global progress and collaboration in the field of celiac disease research.”
    Robert (Bob) Anderson, MB ChB, Ph.D., is the recipient of the Celiac Disease Foundation Prize for Excellence in Celiac Disease Research.
  • The Celiac Disease Foundation thanks our 2023 Global Celiac Disease Research Prize sponsors: Anokion and Immundiagnostik, Inc.
    Celiac disease is a complex genetic autoimmune disorder that affects an estimated 1 in 100 people worldwide.

Global Gastrointestinal Partnering 2016-2023: Trends, Players and Financials of Over 480 Partnerships - ResearchAndMarkets.com

Retrieved on: 
Monday, April 3, 2023
Biotechnology, Pharmaceutical, Health, Chapter Four, Appendicitis, Irritable bowel syndrome, Gastroesophageal reflux disease, Gastritis, Coeliac disease, A-Z, Abdominal pain, Research, Directory, Orientation, Peptic ulcer disease, Irritation, Chapter Three, Chapter One, Crohn's disease, Diarrhea, Chapter Two, Chapter Five, Chapter Six, Collection, Constipation, Inflammatory bowel disease, Extrapyramidal system, Hyperlink, Ulcerative colitis, Video game, Pharmaceutical industry, Music, Animal feed, Esophagitis, Malabsorption, Hernia, Ascites, Hemorrhoid, Pancreatitis, Gastroenteritis, Jaundice, Malnutrition

The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gastrointestinal Partnering 2016-2023: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Gastrointestinal Partnering 2016 to 2023 provides the full collection of gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
  • Chapter 6 provides a comprehensive directory of all gastrointestinal partnering deals by specific gastrointestinal target announced since 2016.
  • In Global Gastrointestinal Partnering 2016 to 2023, available deals and contracts are listed by:

Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program

Retrieved on: 
Monday, April 3, 2023
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Coeliac disease, ADC, Euronext Paris, Antibody-drug conjugate, IPH, Natural killer cell, IPHA, Takeda, Antibody, Vaccine, Innate Immunotherapeutics

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease.
  • Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies.
  • “We are thrilled to be working with Takeda, a company which has been very successful in developing new drugs across multiple therapeutic areas.
  • This agreement expands the application of Innate’s science beyond our oncology focus and demonstrates how our antibody engineering expertise can play a major role in developing Antibody Drug Conjugate formats.

United States Gluten Free Food Industry is Expected to Reach $4.12 Billion by 2028: Customer Eating Habits are Evolving Towards Low-fat and Organic Baked Products - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 28, 2023
Retail, Food, Beverage, Organic Food, Online, Snack, Convenience, Condiment, Beer, Independent Natural Resources, Inc, Dairy, Patient, Specialty store, Food market, Cheese, Growth, Coeliac disease, Meal, Gluten-related disorders, Butter, Elasticity, Milk, Bread, Prevalence, US, Flour, Fast food, Bakery, Others

Gluten is found in wheat, barley, and rye and is what gives dough its elasticity and baked goods their structure.

Key Points: 
  • Gluten is found in wheat, barley, and rye and is what gives dough its elasticity and baked goods their structure.
  • The rising prevalence of celiac disease and non-celiac gluten sensitivity is one of the primary drivers of the gluten-free food market in the United States.
  • According to the Beyond Celiac Report, around 1% of the population in the United States will have celiac disease by 2020.
  • The dairy gluten-free food sector in the United States has grown significantly in recent years, spurred by rising consumer demand for gluten-free choices.

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Retrieved on: 
Thursday, February 9, 2023
Mayo Clinic, Therapy, Internal medicine, Division, Patient, Coeliac disease, Clinical trial, Conference call, Research, Disease, Part, Conference, DRS, ET, Hepatology, Vaccine, Dentistry, Webcast, Rheumatology, Short course immune induction therapy, Gastroenterology

NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced that its Celiac Disease R&D Webcast will take place today, February 9, 2023 from 11:00 am to 1:00 pm ET.

Key Points: 
  • He will focus on the relevance of the pro-inflammatory cytokine interleukin-2 (IL-2) as objective biomarker that correlates with onset and severity of symptoms after gluten exposure and its relevance for clinical celiac disease trials.
  • "We look forward to hosting this deep-dive discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs.
  • The Celiac Disease R&D Day webcast will be held virtually via Zoom.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations .

Chef-Inspired U.S. Brand to Exhibit at Gulfood Show: Russo's New York Pizzeria Set on Franchise Middle East Expansion

Retrieved on: 
Friday, February 3, 2023
Restaurant, Russo's New York Pizzeria, Nakheel Properties, Coeliac disease, Delivery, RSVP, Research, Dubai, Discovery, Nakheel Mall, United Arab Emirates, Heart, Growth, Dubai World Trade Centre, Fast food

HOUSTON, Feb. 3, 2023 /PRNewswire/ -- Chef Anthony Russo, the creative culinary mind, founder and CEO of chef-driven concepts Russo's New York Pizzeria and Russo's Coal-Fired Italian Kitchen, is attending the Gulfood Show AL Mustaqbal plaza HP-J14 Pavilion upon announcing a growth strategy to expand both brands' international footprint across the Middle East, specifically targeting the United Arab Emirates (UAE), Bahrain, Qatar, Kuwait, Turkey, Africa, and Egypt.

Key Points: 
  • the Russo's New York Pizzeria already in the market.
  • The brand plans to add 30 franchise locations to the Middle East region in the next five years.
  • Russo's Restaurants offers a rare franchise opportunity for entrepreneurs interested in proven brands that are entirely chef driven.
  • ft.) for Delivery outlet to full service
    To learn more about Russo's franchise development opportunities, visit

Immunic to Participate in Scientific and Investor Conferences in February

Retrieved on: 
Wednesday, January 25, 2023
Hepatology, Conference, Montreal Neurological Institute and Hospital, Guideline, Cleveland Clinic, Webcast, DHODH, Internal medicine, Regulatory affairs, Regulation, UK Regulators Network, Coeliac disease, Research, Mayo Clinic, Division, Multiple sclerosis, Pharmaceutical industry, Nursing, Rheumatology, Pharmacovigilance, Advisory Committee on Immunization Practices, Gastroenterology

Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.

Key Points: 
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • A live webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations .
  • An archived replay will be available on the company's website for a period of 90 days after the conference.